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ABSTRACT
Objective: To examine the value for money of including peri-
toneal dialysis (PD) or hemodialysis (HD) into the universal
health insurance scheme of Thailand.
Methods: A probabilistic Markov model applied to end-
stage renal disease (ESRD) patients aged 20 to 70 years was
developed to examine the incremental cost-effectiveness
ratio (ICER) of palliative care versus 1) providing PD as an
initial treatment followed by HD if complications/switching
occur; and 2) providing HD followed by PD if complica-
tions/switching occur. Input parameters were extracted
from a national cohort, the Thailand Renal Replacement
Therapy Registry, and systematic reviews, where possible.
The study explored the effects of uncertainty around input
parameters, presented as cost-effectiveness acceptability
frontier, as well as the value of obtaining further informa-
tion on chosen parameters, i.e., partial expected value of
perfect information.
Results: Using a societal perspective, the average ICER of
initial treatment with PD and the average ICER of initial
treatment with HD were 672,000 and 806,000 Baht per
quality-adjusted life-year (QALY) gained (52,000 and
63,000 purchasing power parity [PPP] US$/QALY) com-
pared with palliative care. Providing treatments for younger
ESRD patients resulted in a signiﬁcant improvement of sur-
vival and gain of QALYs compared with the older aged
group. The cost-effectiveness and cost-utility ratios of both
options for the older age group were relatively similar.
Conclusions: The results suggest that offering PD as initial
treatment was a better choice than offering HD, but it would
only be considered a cost-effective strategy if the social will-
ingness-to-pay threshold was at or higher than 700,000 Baht
per QALY (54,000 PPP US$/QALY) for the age 20 group and
750,000 Baht per QALY (58,000 PPP US$/QALY) for age
70 years.
Keywords: dialysis, economic evaluation, renal failure,
Thailand, value of information.
Introduction
The treatment of end-stage-renal disease (ESRD) is rec-
ognized as a major economic and political challenge in
health care [1]. Renal replacement therapy is essential
to many patients suffering from ESRD. It is, however,
one of the most expensive health technologies [2].
Unsurprisingly, policy analysis and economic evalua-
tion of ESRD treatment is among the ﬁrst interventions
to have been assessed, and evaluations have been per-
formed regularly in many settings worldwide [3–15].
There are three major treatment modalities for
patients with ESRD: peritoneal dialysis (PD), hemodi-
alysis (HD), and kidney transplantation. A number of
previous studies conﬁrmed that kidney transplantation
was the most cost-effective strategy and considered the
preferable choice [3–8]. In many settings, however,
including Thailand, the number of kidney donors is
insufﬁcient to meet demand. There are around 200
donated kidneys available each year compared with
the current incidence of 10,000 ESRD patients per year
[16,17].
Thailand has been providing universal health-care
coverage through a tax-based universal health insur-
ance scheme (UC) since 2001 [18]. The scheme pro-
tects a population of 45 million who are not eligible
for Civil Servant Medical Beneﬁt Scheme (CSMBS) or
Social Security Scheme (SSS). Although all treatment
modalities for ESRD are currently covered by CSMBS
and SSS, none of them is included in the UC beneﬁt
package [19]. To date, there is strong pressure from
various stakeholders to provide universal access to PD
and HD for UC beneﬁciaries [20].
This study is one of a series of studies supported by
the National Health Security Ofﬁce (NHSO) to pro-
vide scientiﬁc evidence for policymakers to make deci-
sions on whether to provide dialysis treatments for
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ESRD patients under UC. Using both the NHSO’s and
a societal perspective, the objective of this study was to
assess the value for money of providing PD and HD
for UC patients versus the current practice, i.e., palli-
ative care.
Design and Methods
Overview Options
The standard practice (“palliative care” option)
includes restricted ﬂuid intake, high-dose diuretic,
antihypertensive drugs, calcium, bicarbonate, ferrous
sulfate, blood transfusion, and hospital admission, if
required. Previous evidence has indicated 50% mortal-
ity within 1 to 3 months [19].
Peritoneal dialysis has two main treatment varieties,
either with manual exchange of dialysis ﬂuid (contin-
uous ambulatory peritoneal dialysis—CAPD) or with
automated exchange of dialysis ﬂuid at night. Only
CAPD is offered in Thailand so it has been included in
the analysis [17].
Hemodialysis can be carried out in a hospital, dial-
ysis center, a satellite unit, or in a patient’s home. Hos-
pital and in-center dialysis, however, are the only
options currently available in Thailand [17]. At the
end of 2004, 301 hospitals and dialysis centers, at least
one in every province, offered HD [21].
Analyses and Model
The traditional approach of economic evaluation,
incremental cost-effectiveness analysis, which com-
pares additional costs and health outcomes of moving
from one intervention to alternatives, may be inappro-
priate in this case [2]. Because PD and HD are not
complete substitutes, patients assigned for PD may
require HD while complications such as peritonitis
occur, and vice versa. Hence, this study evaluated the
incremental cost and effectiveness of moving from cur-
rent practice, palliative care, versus 1) providing PD as
initial care followed by HD if complications/switching
occur; and 2) providing HD as initial care followed by
PD if complications/switching occur.
We developed a decision-analytic model and
applied it to ESRD patients aged 20 to 70 years. The
model was used to quantify the costs and effects of the
two alternative long-term managements for ESRD,
starting either with PD or with HD, for each patient
age group. The Markov model structure shown in
Figure 1 illustrates the mutually exclusive health states
that a patient commencing treatment on either PD or
HD may go through, respectively. The states of health
are denoted in the solid-line ovals. We also developed
substates (dotted-line ovals) to reﬂect the difference in
rates of complications between the two treatment
modalities. An arrow indicates that movement from
one state to another is possible. The movement
between each state is determined by probabilities that
were obtained from a national cohort, the Thailand
Renal Replacement Therapy (TRT) Registry, and sys-
tematic reviews, where possible. Because both PD and
HD are lifelong treatments, the model used a 1-year-
cycle length for full health state and 1 month for com-
plication substates.
In the model, patients may start either with PD or
with HD and remain on the same treatment for the
next cycle. Some patients, however, may experience
complications for a month at anytime during a year
cycle. The move between treatments or entry into the
ﬁnal state (death) may or may not be related with the
occurrence  of  complications.  Patients  may  die  of
non-ESRD causes, such as cardiovascular disease, or
patients may move to another treatment because of
dialysis complications, such as catheter-related infec-
tions (for HD) or peritonitis (for PD), or patients may
have nonmedical limitations, such as moving to a new
place where there is no hemodialysis available. In each
case, it was assumed that the event would only happen
at the end of each cycle.
Monte Carlo simulation was used to model costs
and events over a 99-year period to cover the total
period over which the whole cohort would be expected
to survive.
To comply with the guideline set beforehand for
conducting this health economic evaluation [22], and
to be comparable with other economic evaluations
[23], all costs and outcomes were discounted at the
rate of 3.5%. We, however, also explored results with
the discount rates of 0% and 6%.
Outcome Measures
From the review, we found only one small randomized
controlled trial (38 patients) that investigated the rel-
ative efﬁcacy of PD and HD and found no signiﬁcant
difference in 5-year survival (95% conﬁdence interval
Figure 1 Schematic diagram of the Markov
model.
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of hazard ratio between 0.8 and 15.4) after adjusting
for age and comorbidities [24]. A systematic review
conducted by MacLeod et al. also shows that existing
data are not available to allow reliable conclusions to
be drawn about the relative effectiveness of PD and
HD [25]. There are still conﬂicting results in the liter-
ature of nonrandomized observational studies, but
when data are adjusted for comorbid conditions they
show no signiﬁcant difference in patient survival on
PD and HD [25,26]. Our assumption, based on these
sources, is that PD and HD are equally effective in
terms of patient survival.
Using this assumption, we estimated survival rates
for a hypothetical cohort of patients from the TRT
Registry undergoing dialysis. The national database
consisted of records of 6272 patients who underwent
dialysis from 1997 to 2003. In our analyses, we
assumed all patients as having similar treatment. This
does not result in biased estimators of survival but may
underestimate variance. Given limitations of the data-
base, we can only focus on patients’ age at the start of
dialysis as a covariate that might potentially affect
patient prognosis.
Using the statistical software package STATA
(Stata Corp, College Station, TX), we initially applied
the  nonparametric  Kaplan–Meier  approach  [27]  to
ﬁt Kaplan–Meier curves and plot graphs of
log{ } against log(time), which were generally
linear, indicating that a Weibull survival model would
adequately ﬁt the data [28]. We consequently used the
“streg” module of the software to perform maximum
likelihood estimations for parametric regression of the
Weibull survival models (see Table 1).
For the Weibull distribution, the survival function,
which describes the probability of survival as a func-
tion of age [29], is
S(t) = exp[−H(t)]
and
H(t) = λtγ
where H(t) is the cumulative hazard; λ (lambda) is the
scale parameter; t is time in days; and γ (gamma) is the
shape parameter that describes the instantaneous
death rate, the hazard rate h(t), which increases with
age if γ > 1. λ depends on the covariate, age, according
to the formula
λ = exp[(age_coefﬁcient × Age) + cons]
The transitional probability of dying during the
cycle, tp(c), is therefore estimated from the following
formula (where c is the number of cycle):
tp(c) = 1 − exp[H(t − c) − H(t)]
- ( )[ ]log S t
Table 1 Means and standard error (SE) of input parameters
Parameters Mean SE
Parameter
distribution Data source
Weibull survival
Constant value for baseline hazard −11.1771 0.2439 LogNormal TRT
Age coefﬁcient for baseline hazard 0.0347 0.0021 LogNormal TRT
ln(γ) 0.0722 0.0247 LogNormal TRT
Transitional probabilities
Monthly probability of dying among patients with palliative care 0.331 0.1509 Beta [19]
Annual rate of having complications among PD patients 0.3294 0.5739 Gamma [32]
Annual rate of having complications among HD patients 0.2698 0.5194 Gamma [19]
Annual probability of switching from PD to HD 0.0270 0.0054 Beta TRT
Annual probability of switching from HD to PD 0.0064 0.0011 Beta TRT
Direct health-care costs
Lifetime costs of palliative care 18,000 18,000 Gamma [19]
Set-up costs for PD, e.g., peritoneal catheter implantation 47,000 15,000 Gamma Survey
Set-up costs for HD, e.g., arteriovenous graft 21,000 7,000 Gamma Survey
Annual maintenance cost for PD 356,000 45,000 Gamma [33] and survey
Annual maintenance cost for HD 380,000 132,000 Gamma [38]
Total (monthly) cost of treating PD complications 32,000 24,000 Gamma [33] and survey
Total (monthly) cost of treating HD complications 15,000 15,000 Gamma [33] and survey
Annual cost of treating comorbidities, e.g., diabetes 40,000 29,000 Gamma [33,39]
Direct non–health-care costs, e.g., travel costs
Lifetime cost paid by household with palliative care 35,000 35,000 Gamma [39]
Annual cost paid by household with PD 5,000 1,000 Gamma [39]
Annual cost paid by household with HD 33,000 8,000 Gamma [39]
Indirect non–health-care costs, e.g., costs of sick leave
Annual cost paid by household with PD 3,000 600 Gamma
Annual cost paid by household with HD 41,000 8,000 Gamma [39]
Utility parameters
Utility for PD without complication 0.72 0.08 Beta [33–36]
Utility for HD without complication 0.68 0.10 Beta [33–36]
Utility for patients with palliative care/dialysis with complications 0.60 0.15 Beta [33–36]
TRT, Thailand Renal Replacement Therapy Registry.
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The survival graphs shown in Figure 2 reveal that
the mortality rates were predicted to be high among
older patients and increased with age. In this ﬁgure,
however, it can be observed that for all age groups a
great proportion of the cohort reaches 100 years or
more. For example, about 20% of the age 20 group
survives up to 100 years, which is not consistent with
the national ﬁgures for life expectancy in the general
population [30].
This is a common problem found in the modeling of
survival when the length of follow-up of empirical data
is insufﬁcient to capture enough events (4 years for this
case) [31]. An explanation is that the hazard rate used
in the study is for all-cause mortality, so that for
younger dialysis patients the total mortality rate is
mostly mortality due to ESRD, whereas for older
patients there will be a signiﬁcant risk of mortality due
to other causes, e.g., cardiovascular problems. Using
the mortality hazard for age 20 years starting dialysis
to estimate their survival for 99 years may underesti-
mate their risk of mortality due to non-ESRD causes.
As an alternative, we estimated another survival
model that allowed patients to move between esti-
mated survival curves in Figure 2 as their age increases.
The adjusted survival graph from the new model is
presented in Figure 3, which shows more realistic esti-
mations. We applied survival from both models in turn
in our analyses.
Analysis of the national database indicated that the
annual probability of switching from PD to HD was
0.0270 (SE 0.0054) and the probability of switching
from HD to PD was 0.0064 (SE 0.0011).
The rate of complications among those with PD and
HD was not routinely reported in the TRT Registry.
Therefore, we did a systematic search of national lit-
erature from MUCC-OPAC (Mahidol University),
Chulalinet (Chulalongkorn University), CMUL OPAC
(Chiangmai University), INNOPAC web (Khon Kaen
University), and OPAC PSU (Prince of Songkla Univer-
sity) using the keywords “dialysis,” “renal dialysis,”
“hemodialysis,” and “peritoneal dialysis.” Two inde-
pendent researchers reviewed whether all abstracts and
full manuscripts matched the inclusion criterion previ-
ously set by the team. If more than one study were
identiﬁed, meta-analysis of data was proposed.
The annual rate of having peritonitis among
patients with PD was 0.3294 (SE 0.5729) [32] and the
annual rate of having vascular access-related compli-
cations among patients with HD was 0.2698 (SE
0.5194) [19].
Based on an assumption of a short half-life of
patients with palliative care (1–3 months) [19], the
mean and SE of the monthly probability of ESRD
patients dying without dialysis were 0.3331 and
0.1509, respectively.
Quality-Adjusted Survival
We adjusted outcomes for quality of life (QoL) using
published utility estimates from a systematic search of
similar databases and keywords used in outcome
measures. We identiﬁed 12 studies reporting QoL for
ESRD patients but subsequently excluded eight studies
in which results were not presented to compare QoL
among treatment strategies and/or were only qualita-
tive descriptions. Finally, we included the four remain-
ing studies, all of which interviewed ESRD patients.
All studies employed multiattribute utility measure-
ments, e.g., Health Utility Index, EQ-5D [33–36].
Meta-analysis using a random effects approach found
that the QoL of ESRD patients without dialysis was
0.60 (SE 0.15). Without complications, the QoL of
patients with PD was 0.72 (SE 0.08) and the QoL of
patients with HD was 0.68 (SE 0.10). No study
reported the QoL of patients with dialysis and compli-
cations. We applied the QoL of patients without dial-
ysis to those with dialysis and complications.
Costs
Costs were derived from a systematic search of Thai
published and gray literature, selecting the most up-to-
date reports. They included all items of resources used,
i.e., capital, labor and material costs of health-care
providers, and real and opportunity costs lost by
patients and relatives, i.e., patient treatment time, time
for informal care, and cost for sick leave.
Figure 2 Survival graphs by age group (up to 4 years and projected using
the Thailand Renal Replacement Therapy Registry).
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Figure 3 Adjusted survival (allowing patients to move between survival
curves in Figure 2 as their age increases) using sensitivity analysis.
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In addition, although most economic evaluations
include future costs only for related illnesses [37], we
considered that the cost of unrelated medical care
might be considerable in this particular case because
the interventions increase length of life and the patient
population is likely to have comorbidities, e.g., diabe-
tes or cardiovascular disease. Hence, we counted the
cost of treating comorbidities as a program cost for
each extended life-year (LY).
Brieﬂy, the provider’s costs for offering HD and PD
were from a national costing survey carried out by
Tisayathikom et al. [38] and from a master’s degree
thesis by Sriwajana [33], while the patient’s costs were
from a study conducted by Homvijitkul [39]. We also
conducted a micro-costing survey in two public hospi-
tals (Prince of Songkla hospital and ChiangKhum hos-
pital) and one private hospital (Viphavadee hospital)
for cost items where no published data were identiﬁed.
All costs shown in Table 1 are reported in 2004
Thai Baht for each state of health within the Markov
model. For intercountry comparison, costs have been
converted into international dollars using purchasing
power parity (PPP) US$ exchange rates at 1 US$
(2004) = 12.868 Thai Baht [40].
Uncertainty Analysis
A probabilistic sensitivity analysis using a second-
order Monte Carlo simulation was carried out in
Microsoft Ofﬁce Excel 2003 (Microsoft Corp., Red-
mond, WA) [29]. All input parameters were assigned a
probability  distribution  to  reﬂect  the  feasible  range
of values that each input parameter could attain [41].
The beta-distribution was the choice of distribution
for probability and utility parameters, which were
bounded zero—one, and the gamma-distribution,
which ensures positive values, was modeled for all rate
and  unit  cost  parameters.  The  normality  on  the
log-odds scale with covariance matrix and Cholesky
decomposition [42] was applied for survival
parameters.
The simulation then drew one value from each dis-
tribution simultaneously and calculated cost and effec-
tiveness pairs. This process was repeated 1000 times to
provide a range of possible values given the speciﬁed
probability distributions. Because there is no linear
relationship between inputs and outputs in the
Markov model [43], all costs, outcomes, and cost-
effectiveness ratios provided in the Results section are
expressed as the average value from the probabilistic
sensitivity analysis.
Furthermore, because net beneﬁts are not always
normally distributed, a cost-effectiveness acceptability
curve may wrongly present some strategies as subop-
timal, but which have a higher probability of being
cost-effective [44]. Thus, the results are presented as a
cost-effectiveness acceptability (CEAcc) frontier, which
determines the intervention giving the maximum
expected net beneﬁt for each value of the ceiling ratio
[29].
We also determined an uncertain parameter’s
importance using the utility theory framework. The
analysis of partial expected value of perfect informa-
tion (EVPI) was performed to determine whether dif-
ferent values of a particular input parameter lead to
different optimum decisions, and if so, how much the
expected loss under alternative optimum decisions
varies [45,46].
If θ is the set of parameters for the model, with
deﬁned prior probability distributions; t is the set of
possible decisions or strategies; and NB(t, θ) is the
function of net beneﬁt for decision t and parameters θ,
the expected net beneﬁt given no further information
can be written as
maxt[EθNB(t, θ)]
The expected net beneﬁt given full information is
Eθ[maxtNB(t, θ)]
and overall EVPI equals to
Eθ[maxtNB(t, θ)] − maxt[EθNB(t, θ)]
This is expressed in Baht per patient. To give a ﬁnal
value for the Thai context, we then multiplied by the
incidence of 10,000 new ESRD cases per year and
assumed that the current technology would be in oper-
ation for 10 years [19].
To quantify the value of obtaining further informa-
tion on chosen parameters, partial EVPI is the differ-
ence between the expected value of a decision made
with perfect information about a particular vector of
the parameters (θ) and the current optimal decision
[47].
With perfect information θi is the known vector of
the parameters of interest, θ; then the expected beneﬁt
of a decision made would now be found by averaging
over the uncertainty in θ that remains once we know θi
and then by selecting the optimal treatment that pro-
vides maximum expected net beneﬁt:
At this stage, however, we do not have perfect infor-
mation on θi, so the expected value of a decision made
with perfect information about θi is found by averag-
ing over the uncertain ranges of the parameters θi and
can be presented as
The additional value of collecting perfect informa-
tion on a subset θi of uncertain model parameters is
therefore given by the following equation:
The analysis of partial EVPI requires an explicit
statement of the value of the ceiling ratio, and because,
max ,|t E ttq q qNB  ( )[ ]
E E ti t tq q q qmax || NB( )[ ]
E E t E ti t tt tq q q q qq qmax | max ,| |NB NB( )[ ] - ( )[ ]
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unfortunately, there is no such accepted threshold for
adopting health technologies in Thailand, we applied
the threshold that is recommended by the commis-
sion on Macroeconomics and Health, which suggests
the use of three times of gross domestic product (GDP)
per capita as the threshold for consideration in devel-
oping countries [48]. This would indicate a ceiling
value in Thailand of 270,000 Baht per quality-
adjusted life-year (QALY) based on 2004 Thai GDP
and population [49].
Results
Using the government perspective, the total program
cost of palliative care was 72,000 Baht, accounting for
32% of the program cost from a societal perspective
(224,000 Baht). The palliative care option yielded 0.34
life-year (LY), or 0.20 QALY. These costs and out-
comes of palliative care were equivalent for all age
groups.
Compared with providing PD as the ﬁrst-line treat-
ment, the introduction of HD offered more health ben-
eﬁts, LYs saved, and QALYs gained, and was more
costly for all age groups (Tables 2 and 3). Total lifetime
costs borne by the NHSO accounted for 95% for
offering PD as an initial treatment, and 85% for offer-
ing HD as an initial treatment, for all age groups,
resulting in comparable economic evaluation results
both using either the NHSO’s or a societal viewpoint.
Given the effects of discounting on long-term costs, it
is noteworthy that the lifetime costs derived from the
model with unadjusted survival and the model with
adjusted survival were similar. This is shown in
Tables 4 and 5.
Both for models with adjusted and nonadjusted sur-
vival, the incremental costs of providing the “PD ﬁrst”
option ranged from 466,000 Baht per LY saved or
667,000 Baht per QALY gained for patient aged
20 years to 497,000 Baht per LY or 700,000 Baht per
QALY gained for patient aged 70 years using a societal
perspective. Slightly higher, i.e., less favorable, cost-
effectiveness and cost-utility ratios were observed if
“HD ﬁrst” is introduced in the UC beneﬁt package.
Uncertainty Analysis
The results of the probabilistic sensitivity analysis
using a societal viewpoint are presented by CEAcc
frontier in Figure 4. We compared the simulation
results for patients aged 20 years (black line) with
those for patients aged 70 years (gray line), which are
quite similar, with one exception. The CEAcc frontier
suggests that for ceiling ratios less than 650,000 and
700,000 Baht per QALY for age groups 20 and
70 years, respectively, providing care without dialysis
for ESRD patients was the most appropriate. If poli-
cymakers are, however, willing to pay more than
Table 2 Lifetime cost for providing peritoneal dialysis and hemodialysis as an initial treatment by age group and view point of analysis
Age
(year)
Unadjusted survival Adjusted survival 
Peritoneal dialysis Hemodialysis Peritoneal dialysis Hemodialysis 
Societal
perspective
NHSO’s
perspective
Societal
perspective
NHSO’s
perspective
Societal
perspective
NHSO’s
perspective
Societal
perspective
NHSO’s 
perspective
20 8,277,000 7,804,000 9,286,000 7,956,000 8,277,000 7,804,000 9,286,000 7,956,000
30 7,262,000 6,823,000 8,206,000 7,013,000 7,262,000 6,823,000 8,206,000 7,013,000
40 6,135,000 5,737,000 6,997,000 5,807,000 6,135,000 5,737,000 6,997,000 5,807,000
50 5,062,000 4,826,000 5,771,000 5,028,000 5,062,000 4,826,000 5,771,000 5,028,000
60 4,096,000 3,901,000 4,696,000 4,011,000 4,096,000 3,901,000 4,696,000 4,011,000
70 3,286,000 3,126,000 3,775,000 3,235,000 4,233,000 3,126,000 4,353,000 3,235,000
Costs are given to nearest 1000 Baht, 2004 price levels.
The ﬁgures are not incremental but absolute numbers. Conversion to incremental values compared with palliative care can be performed by subtracting 224,000 Baht for a soci-
etal perspective and 72,000 Baht for the NHSO’s perspective for all age groups.
NHSO, National Health Security Ofﬁce.
Table 3 Health outcomes of providing peritoneal dialysis and hemodialysis as an initial treatment by age group
Age
(year)
Unadjusted survival Adjusted survival 
Life-years gained QALYs gained Life-years gained QALYs gained 
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
Peritoneal 
dialysis Hemodialysis
20 17.65 17.65 12.27 11.89 17.65 17.65 12.32 11.89
30 15.32 15.32 10.67 10.25 15.34 15.34 10.71 10.26
40 12.96 12.96 9.03 8.67 12.93 12.93 9.01 8.65
50 10.60 10.60 7.44 7.14 10.58 10.58 7.42 7.11
60 8.45 8.45 5.92 5.70 8.41 8.41 5.92 5.65
70 6.53 6.53 4.60 4.38 9.21 9.21 6.43 6.13
The ﬁgures are not incremental but absolute numbers. Conversion to incremental values compared with palliative care can be performed by subtracting 0.34 for life-year gained
and 0.20 for QALY for all age groups.
QALYs, quality-adjusted life-years.
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700,000 Baht per QALY for age group 20 years and
750,000 Baht per QALY for age group 70 years, pro-
viding “PD ﬁrst” was the optimal choice.
With the existence of uncertainty around input
parameters of alternative treatment modalities,
Figure 5 illustrates the expected opportunity loss of
making a wrong decision for patients aged 50 years
(the average age among ESRD patients in Thailand).
Overall EVPI of treating 10,000 new ESRD cases per
year and for a 10-year time period was highest
(260,000 million Baht) at a ceiling ratio of 650,000
Baht per QALY.
Because it was certain that palliative care was the
best option at the ceiling ratio of 270,000 Baht per
QALY (Fig. 5—overall EVPI = 0 at the ceiling ratio
270,000 Baht), there is no partial EVPI at that partic-
ular threshold. We, however, decided to examine the
importance of each input parameter in the model, at
least, as a proxy for future research in other settings.
Thus, we took the point of maximum overall EVPI
Table 4 Results of economic evaluation of providing peritoneal and hemodialysis as an initial treatment compared to palliative care,
using the societal perspective
Age
(year)
Unadjusted survival Adjusted survival 
Baht per life-year saved Baht per QALY gained Baht per life-year saved Baht per QALY gained 
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
20 466,000 525,000 667,000 777,000 466,000 525,000 667,000 777,000
30 470,000 533,000 671,000 795,000 470,000 533,000 671,000 795,000
40 470,000 539,000 672,000 803,000 470,000 539,000 672,000 803,000
50 473,000 543,000 672,000 806,000 473,000 543,000 672,000 806,000
60 480,000 555,000 677,000 821,000 480,000 555,000 677,000 821,000
70 497,000 575,000 700,000 850,000 497,000 575,000 700,000 850,000
Costs are rounded up to nearest 1000 Baht, 2004 price levels.
QALY, quality-adjusted life-year.
Table 5 Results of economic evaluation of providing peritoneal and hemodialysis as an initial treatment compared to palliative care,
using NHSO’s perspective
Age
(year)
Unadjusted survival Adjusted survival 
Baht per life-year saved Baht per QALY gained Baht per life-year saved Baht per QALY gained 
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
Peritoneal
dialysis Hemodialysis
20 447,000 456,000 641,000 675,000 447,000 456,000 641,000 675,000
30 451,000 463,000 645,000 691,000 451,000 463,000 645,000 691,000
40 449,000 455,000 643,000 678,000 449,000 455,000 643,000 678,000
50 463,000 483,000 657,000 714,000 463,000 483,000 657,000 714,000
60 472,000 486,000 670,000 716,000 472,000 486,000 670,000 716,000
70 495,000 512,000 696,000 759,000 495,000 512,000 696,000 759,000
Costs are rounded up to nearest 1000 Baht, 2004 price levels
NHSO, National Health Security Ofﬁce; QALY, quality-adjusted life-year.
Figure 4 Cost-effectiveness acceptability
frontier.
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(ceiling ratio of 650,000 Baht per QALY) to quantify
the expected additional value of collecting perfect
information on each input parameter, partial EVPI.
Figure 6 reveals that, among all uncertain model
parameters, the maintenance cost of the PD and HD
options were the parameters with the ﬁrst and second
highest partial EVPI, respectively. Utility values for
patients treated by PD and HD, costs of treating
comorbidity, and survival function were among the
important parameters.
Because it is debatable whether to include future
unrelated medical care costs resulting from lifesaving
interventions when performing economic evaluations
[37,50], in our analysis we thus assessed the impact of
excluding the costs of treating comorbidities for each
LY gained. We found that, without the costs of treating
Figure 5 Population expected value of perfect
information for a model using the 50 years age
group with adjusted survival.
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Figure 6 Expected value of perfect information (EVPI) for input parameters. pDoNot, probability of dying among patients with palliative treatment;
pComPD, rate of having complications among PD; pComHD, rate of having complications among HD; pHDtoPD, probability of switching from HD to PD;
pPDtoHD, probability of switching from PD to HD; SurvFunction, survival estimation; cPalliative, health-care cost of palliative care; cChroHD, health-care
cost of hemodialysis; cChroPD, health-care cost of peritoneal dialysis; cPeritonitis, health-care cost of treating PD complications; cCoMorbid, health-care
cost of treating comorbid conditions; cIdMDonot, direct non–health-care cost of palliative treatment; cIdMHD, direct non–health-care cost of hemo-
dialysis; cIdMPD, direct non–health-care cost of peritoneal dialysis; cPatientHD, indirect non–health-care cost of hemodialysis; cPatientPD, indirect non–
health-care cost of peritoneal dialysis; uPDnoCom, utility for PD without complication; uHDnoCom, utility for HD without complication; uCom, utility
for patients with complications.
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comorbidities, all ICERs of both PD and HD in terms
of Baht/LY gained and Baht/QALY gained were
reduced around 9% to 10% across age groups
(because the model used no age-speciﬁc average
medical care costs).
In the analysis using the alternative discount rates
of 0% and 6%, we found that the rates above and
below the actual discount rate used for the reference
case (3.5%) had no impact on the overall conclu-
sions—offering PD as an initial treatment was always
superior to HD for all age groups, and providing treat-
ment to younger patients was superior to that for
elders (see Fig. 7). Furthermore, although there was
not much difference among ICERs using different dis-
count rates, it can be seen that the lower the rate of
discounting the lower the ICER.
Discussion
The results indicate that the government should not
include dialysis services for ESRD patients unless
social willingness to pay or the ceiling ratio is at or
higher than 700,000 Baht per QALY for young
patients (age 20 years) and 750,000 Baht per QALY
for older people (age 70 years). Although, there is no
agreed threshold for adopting health technologies in
Thailand, the threshold of 700,000 is almost three
times higher than that recommend by the commission
on Macroeconomics and Health.
If decision-makers are willing to pay 700,000 Baht
per QALY or more, then providing PD as an initial
treatment is the optimal decision because it dominated
the HD option at any value of the ceiling ratio given
the assumption of equal survival between PD and HD.
In  subgroup  analysis,  it  is  interesting  to  note
that providing treatments for younger ESRD patients
resulted in a signiﬁcant improvement of survival and
gain of QALYs compared with the older age group. We
found, however, that cost-effectiveness and cost-utility
ratios among all subgroups were relatively similar.
This could be explained, as Manns et al. [50] pointed
out, by the fact that the inclusion of future costs, i.e.,
costs of dialysis of extended survival, would largely
affect the economic evaluation results, so that even rel-
atively inexpensive interventions that extend the sur-
vival of dialysis patients may not be cost-effective, as
long as the treatment must be continued.
At this stage, no ﬁnal decision has been made by
Thai government whether to include PD or HD in the
UC beneﬁt package. We believe that this evidence
needs to be considered alongside other policy issues,
e.g., equity grounds, ethical principles, or ﬁnancial
implications, all of which are being considered. The
NHSO is also considering launching a process of
national consensus, in 2006, through a series of public
hearings, to solicit public opinions on the rationing of
care for ESRD patients in Thailand.
The results of this study are not in agreement with
the conclusion made by Winkelmayer et al. [2]. They
reviewed 13 economic evaluation studies on renal
replacement therapy published between 1968 and
1998 and concluded that the cost-effectiveness of
center hemodialysis were within a narrow range of
US$55,000 to US$80,000 per LY saved (all ﬁgures
were adjusted using PPP US$ exchange rate). Our
study found a lower ﬁgure for Thailand (US$43,000
per LY saved). This ﬁnding could possibly be explained
by the fact that the study of Winkelmayer et al. was
dominated by evidence from developed countries,
because 12 out of 13 studies were conducted in United
States, United Kingdom, Canada, Sweden, New Zea-
land, and The Netherlands.
Nevertheless, our results are still higher than the
results of a study conducted in Brazil [5], which was
included in the work of Winkelmayer et al., and a
newer publication from Malaysia [51]. Using a pro-
vider (NHSO) perspective, our study ﬁnds that the
cost-effectiveness of PD and of HD were US$37,000
Figure 7 Incremental cost-effectiveness ratios
(ICER) using different discount rates by age
group. Note: to present the differences of the
results, we modiﬁed scale in x-axis starting with
500,000 Baht per QALY.
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and US$38,000 per LY saved. The Brazilian study indi-
cated that the cost-effectiveness of PD and of HD were
US$12,000 and US$11,000 per LY saved, respectively,
and a recent report by Hooi [50] revealed that the cost-
effectiveness of PD and of HD in Malaysia were
US$8000 and US$9000 (2001) per LY saved. These
differences may partly be explained by the fact that the
Brazilian and Malaysian studies did not include future
medical costs of treating comorbidities from extended
LYs.
There are some limitations regarding the availabil-
ity of data used in the model. We carried out subgroup
analysis by modeling age-speciﬁc survival from the
TRT Registry, but we have no information available
to model age-speciﬁc expenditures. Thus, the model
applied the same provider and patient costs for all sub-
groups. Using non–age-speciﬁc costs may have under-
estimated or overestimated some cost items, e.g., cost
for sick leave or cost of treating comorbidities, which
are expected to vary across age groups.
Nevertheless, it is arguable that the magnitude of
cost-effectiveness and cost-utility ratios were largely
dependent on the estimated future cost of dialysis, PD
or HD, and these costs were likely to be comparable
across all subgroups. Also, although costs applied in
the analysis included all items of resources used, the
costs of staff training, which would be large for this
particular form of care, were excluded.
Furthermore, we assumed independence between
the occurrence of complications and switching
between treatment modalities in the model. Thus, it is
likely to have had an impact on the probabilistic sen-
sitivity analysis and the CEAcc frontier.
Because we wanted to use Thai data and perform
sub-age group analysis, and because there is no effec-
tiveness evidence from randomized controlled trials or
meta-analysis available to perform that, we had to esti-
mate effectiveness from the registry database, which
gives an equal survival for PD and HD. This approach,
however, does not allow analysts to explore the uncer-
tainty surrounding the effectiveness of each treatment
and to quantify its impact and value for obtaining
more information. As a result, we recommend that a
high quality synthesis of the evidence on PD versus HD
survival should be conducted.
Finally, the utility value for dialysis with complica-
tions is assumed equal to the utility of having no dial-
ysis, which may have underestimated the uncertainty
in this parameter. Nevertheless, given the rare inci-
dence and relatively short duration of dialysis with
complications, we still believe that the utility of
dialysis with complications would have little effect on
the overall results, as indicated by the partial EVPI
analysis.
We believe that the methods and results of this
study provide an important contribution to the evalu-
ation of the value for money of alternative modes of
management of ESRD patients in Thailand and other
health-care settings, especially in developing countries,
where such evidence is rarely available. The methods
used in this study can be applied to future evaluations
of health-care technologies.
There are two features of the methods that deserve
particular emphasis. First, rather than evaluating PD
or HD alone, we evaluated the value for money of pro-
viding PD or HD as the ﬁrst-line treatment, which per-
mits patients subsequently to move between treatment
modalities. For example, we found that among people
whose initial treatment modality was PD, 77% of their
time on dialysis (LY saved) was from PD, while among
people initially treated by HD 96% of their LY saved
was from HD. This approach allows the evaluation of
policy options known as “adoption decision” rather
than assume adherence to a particular technology. In
our model, both technologies would need to be avail-
able but used at different levels.
Second, the study extensively evaluated the effects
of uncertainty around input parameters, which is com-
mon in decision modeling. The model is fully proba-
bilistic and the results are comprehensive to handle the
real-life situation faced by policy decision-makers who
need to make a judgment under suboptimal informa-
tion. We hope that this study would also facilitate the
wider use of such methods in future health economic
evaluation studies so that policymakers can take the
beneﬁts from the approach.
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